Supplementary Figure S6 from PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models

2026 Open access

Read full text
Authors: Dejan Juric, Kyung Song, Radia Marie Johnson, Melissa Kate Accordino, Philippe Lucien Bedard, Andrés Cervantes, Valentina Gambardella, Erika Paige Hamilton, Antoîne Italiano, Kevin Kalinsky, Ian E. Krop, Mafalda Oliveira
+34 more Cristina Saura, Peter Schmid, Nicholas C. Turner, Andreea Varga, Steven B. Gendreau, Michael S.H. Hwang, Zheng Kuang, Jeffrey Lau, Eva Lin, Trang Pham, Danilo Maddalo, Matthew G. Rees, Melissa M. Ronan, Jennifer A. Roth, Scott E. Martin, Nicole M. Sodir, Ethan S. Sokol, Zachary J. Whitfield, Alice Wong, Robert L. Yauch, Junko Aimi, Sravanthi Cheeti, Jill O. Fredrickson, Stephanie Hilz, Marc A. Hafner, Katherine E. Hutchinson, Yanling Jin, Ubong Peters, Daniel Zingg, Stephanie Royer‐Joo, Noopur Shankar, Jennifer L. Schutzman, Komal Jhaveri, Anwesha Dey
DOI: 10.1158/1078-0432.31006729
Cited by: 0

Abstract

Effects of inavolisib and FGFR2 inhibition on downstream signaling in FGFR2-high and FGFR2-low expressing cell lines

Fields of Study & Subjects

Fibroblast Growth Factor Research Sympathectomy and Hyperhidrosis Treatments Eosinophilic Disorders and Syndromes

Publication details

Publication date
6 January 2026